Generic Raloxifene

Buy Generic Raloxifene () without prescription in Canada

In our Canadian pharmacy, you can buy Raloxifene without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) used for the prevention and treatment of postmenopausal osteoporosis and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. It works by acting like estrogen on bone, helping to maintain bone density and reduce the risk of vertebral fractures, while blocking the effects of estrogen on breast and uterine tissue, thereby lowering the risk of hormone‑sensitive breast cancer without stimulating the uterine lining.

Usual adult dose: The recommended dose is 60 mg taken orally once daily, with or without food. The tablet can be taken at any time of day. Adequate calcium and vitamin D intake is essential; if dietary intake is insufficient, supplementation should be added. Raloxifene is intended for long‑term therapy in postmenopausal women and should be used as part of a comprehensive management plan that includes weight‑bearing exercise and a healthy diet.

Dosage form: Oral film‑coated tablet, 60 mg (as raloxifene hydrochloride).

Onset of action: Effects on bone turnover markers can be seen within 3 to 6 months of continuous daily therapy. The full benefit on bone mineral density and fracture risk reduction requires at least 1 to 2 years of treatment and is maintained with ongoing use. For breast cancer risk reduction, the protective effect accumulates over time with continued therapy.

Duration of action: The elimination half‑life of raloxifene is approximately 27 to 33 hours, supporting once‑daily dosing. The clinical benefits on bone and breast tissue persist only as long as treatment is continued; discontinuation leads to gradual loss of bone density and a return of breast cancer risk toward baseline.

Alcohol recommendation: Alcohol consumption should be limited during treatment with Raloxifene. Heavy alcohol intake is a known risk factor for osteoporosis and falls, and it may increase the risk of venous thromboembolic events. Moderate alcohol consumption (no more than one drink per day) is generally considered acceptable.

Most common side effects: Hot flushes (up to 25%), leg cramps (6‑9%), peripheral oedema (swelling of the hands or feet), and flu‑like symptoms. These effects are most common during the first 6 months of therapy and often diminish over time. Rare but serious side effects include an increased risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism), which is similar in magnitude to that of estrogen therapy, and a small increase in the risk of fatal stroke.

Would you like to try Raloxifene without a prescription?

General Information about Raloxifene

• INN (International Nonproprietary Name): Raloxifene (as raloxifene hydrochloride).
• Brand names available in Canada: Evista® (Eli Lilly Canada Inc.) is the original brand‑name product. Generic versions include APO‑Raloxifene (Apotex Inc.), Sandoz Raloxifene (Sandoz Canada Inc.), PMS‑Raloxifene (Pharmascience Inc.), TEVA‑Raloxifene (Teva Canada Limited), and others.
• ATC code: G03XC01 (selective estrogen receptor modulators).
• Dosage forms and strengths: Oral film‑coated tablets: 60 mg (as raloxifene hydrochloride). The tablet is white, elliptical, and film‑coated.
• Manufacturers in Canada: Eli Lilly Canada Inc. (Evista), Apotex Inc., Sandoz Canada Inc., Pharmascience Inc., Teva Canada Limited, and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Marketed. DINs: 02239055 (Evista 60 mg), 02446982 (Sandoz Raloxifene 60 mg), among others. First approved in Canada in 1998.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. A valid prescription from a licensed Canadian healthcare professional is required.

Mechanism of Action and Pharmacology

Raloxifene is a nonsteroidal benzothiophene derivative that belongs to the class of selective estrogen receptor modulators (SERMs). It binds with high affinity to estrogen receptors (ER‑α and ER‑β) and exerts tissue‑specific estrogen‑agonist or estrogen‑antagonist effects. In bone, raloxifene acts as an estrogen agonist: it reduces the number and activity of osteoclasts, slows bone resorption, and helps preserve bone mineral density, thereby reducing the risk of vertebral (spinal) fractures. In the breast, raloxifene acts as an estrogen antagonist, inhibiting estrogen‑stimulated proliferation of breast epithelial cells and reducing the risk of invasive breast cancer. In the endometrium (lining of the uterus), raloxifene does not exert estrogen‑agonist effects, which means it does not stimulate endometrial proliferation and does not increase the risk of endometrial cancer—a key advantage over tamoxifen.

Raloxifene is rapidly absorbed after oral administration, with approximately 60% of an oral dose absorbed. The absolute bioavailability is low (~2%) due to extensive first‑pass hepatic metabolism via glucuronidation; raloxifene is not metabolized by cytochrome P450 enzymes. The drug undergoes enterohepatic recycling, which contributes to its long elimination half‑life of approximately 27 to 33 hours, supporting once‑daily dosing. Steady‑state plasma concentrations are achieved after 3 to 4 weeks of daily administration. Raloxifene is highly protein‑bound (98–99%) and is excreted primarily in the faeces as glucuronide conjugates; less than 0.2% is excreted unchanged in the urine.

Indications

• Prevention of osteoporosis: For the prevention of osteoporosis in postmenopausal women who are at risk of developing the disease.
• Treatment of osteoporosis: For the treatment of postmenopausal osteoporosis to reduce the risk of vertebral (spinal) fractures. Raloxifene has not been shown to reduce the risk of non‑vertebral or hip fractures.
• Reduction of invasive breast cancer risk: For the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis, and for the reduction of the risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.
• Raloxifene is not indicated for the treatment of breast cancer or for the prevention of cardiovascular disease. It is not indicated for use in premenopausal women, men, or children.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Raloxifene is absolutely contraindicated during pregnancy and in women who may become pregnant. It is a SERM with the potential to cause fetal harm. If pregnancy occurs, the drug must be discontinued immediately, and the patient should be informed of the potential hazard to the fetus. Women of childbearing potential must use effective non‑hormonal contraception.
• Breastfeeding: It is not known whether raloxifene is excreted in human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment. A decision must be made whether to discontinue breastfeeding or to discontinue the drug.
• Paediatrics (< 18 years): Safety and efficacy have not been established in children. Raloxifene is not indicated for paediatric use.
• Elderly: No dose adjustment is required based on age alone. The majority of women in clinical trials were aged 65 years and older. Elderly patients may be at increased risk of venous thromboembolism and stroke; appropriate precautions should be taken.
• Venous thromboembolism (VTE): Raloxifene significantly increases the risk of deep vein thrombosis and pulmonary embolism, similar in magnitude to the risk observed with estrogen therapy. The risk is highest during the first 4 months of treatment. Raloxifene should be discontinued at least 72 hours before and during prolonged immobilisation (e.g., post‑surgery, prolonged bed rest). Patients should be advised to move their legs periodically during travel. Women with a history of VTE or those at high risk should use raloxifene only after careful risk‑benefit assessment.
• Stroke and cardiovascular disease: Raloxifene is associated with a small increase in the risk of fatal stroke (absolute risk increase of approximately 1.2 per 1,000 woman‑years). It should not be used in patients with a history of stroke or transient ischaemic attack (TIA). Raloxifene is not indicated for the prevention of cardiovascular disease and should not be used for this purpose.
• Hepatic impairment: Raloxifene is extensively metabolized in the liver and should be used with caution in patients with hepatic impairment, including those with a history of cholestatic jaundice. Contraindicated in severe hepatic impairment.
• Renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Raloxifene should be used with caution in patients with severe renal impairment (creatinine clearance < 30 mL/min) because of limited data.
• Endometrial safety: Raloxifene does not stimulate the endometrium and is not associated with an increased risk of endometrial cancer. Any unexplained uterine bleeding should be investigated promptly.
• Hypertriglyceridemia: Raloxifene may cause small increases in serum triglycerides. In women with pre‑existing hypertriglyceridemia, serum triglycerides should be monitored, and the drug should be used with caution.
• Concomitant estrogen therapy: Raloxifene should not be used concurrently with systemic estrogen or hormone replacement therapy, as the safety of this combination has not been established.
• Allergy: Do not take Raloxifene if you have a known hypersensitivity to raloxifene hydrochloride or any excipient in the tablet formulation.

Driving and alcohol

Raloxifene is not known to impair the ability to drive or operate machinery. However, some patients may experience dizziness or flu‑like symptoms, particularly at the start of therapy. Patients should ensure they are not adversely affected before driving or engaging in hazardous activities. Alcohol consumption should be limited during treatment. Heavy alcohol intake is a risk factor for osteoporosis, falls, and thromboembolic events, and may counteract some of the skeletal benefits of raloxifene. Moderate alcohol consumption (no more than one drink per day) is generally acceptable.

Dosage Instructions

• Standard adult dose (postmenopausal women): 60 mg taken orally once daily, with or without food. The tablet may be taken at any time of day. Adequate calcium (at least 1,000 mg/day) and vitamin D (at least 800 IU/day) intake is essential; supplements should be used if dietary intake is inadequate.
• Administration: Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet. Raloxifene may be taken without regard to meals. A consistent daily routine (e.g., taking the tablet at the same time each morning or evening) helps ensure adherence.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next scheduled dose, skip the missed dose and resume the regular once‑daily schedule. Do not double the dose.
• Duration of therapy: Raloxifene is intended for long‑term therapy. The need for continued treatment should be reassessed periodically. Bone mineral density should be monitored every 1 to 2 years. If the drug is discontinued, the protective effects on bone and breast tissue will gradually wane.
• Discontinuation for immobilisation: Raloxifene should be discontinued at least 72 hours before any prolonged immobilisation (e.g., major surgery, extended bed rest) and resumed only after the patient is fully mobile, to reduce the risk of venous thromboembolism.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Hot flushes (up to 25%), vasodilation (flushing), and flu‑like symptoms (influenza syndrome).
• Common side effects (1‑10%): Leg cramps (6‑9%), peripheral oedema (swelling of hands, feet, or ankles), arthralgia, sweating, and insomnia. Hot flushes and leg cramps are most common in the first 6 months of therapy and tend to diminish over time.
• Less common but serious side effects: Venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis (risk similar to estrogen therapy; incidence ~1‑2 per 1,000 woman‑years). Fatal stroke (absolute risk increase ~1.2 per 1,000 woman‑years over 5 years). Endometrial polyps and, rarely, endometrial cancer have been reported, but the risk is not significantly increased.
• Post‑marketing reports: Rare cases of Stevens‑Johnson syndrome, erythema multiforme, and anaphylaxis have been reported.
• Contraindications: Active or past history of venous thromboembolism (deep vein thrombosis, pulmonary embolism, retinal vein thrombosis). Pregnancy and in women who may become pregnant. Breastfeeding. Severe hepatic impairment. Known hypersensitivity to raloxifene hydrochloride or any excipient in the formulation. Unexplained uterine bleeding. Concomitant systemic estrogen or hormone replacement therapy.

Drug Interactions

• Warfarin and other coumarin anticoagulants — moderate interaction: Raloxifene may reduce the prothrombin time and decrease the anticoagulant effect of warfarin. Close monitoring of the International Normalised Ratio (INR) is recommended if raloxifene is co‑administered with warfarin; warfarin dose adjustment may be required.
• Cholestyramine — major interaction: Cholestyramine, an anion‑exchange resin, significantly reduces the absorption and enterohepatic recycling of raloxifene. Concomitant use should be avoided; if both are required, raloxifene should be taken at least 2 hours before or 4–6 hours after cholestyramine.
• Other highly protein‑bound drugs: Raloxifene is extensively protein‑bound (98–99%). Caution should be exercised when co‑administered with other highly protein‑bound drugs (e.g., NSAIDs, diazepam, phenytoin), as displacement interactions are possible but have not been shown to be clinically significant.
• Estrogen and hormone replacement therapy — contraindicated: The safety of concomitant use of raloxifene with systemic estrogen has not been established; concurrent use is not recommended.
• Calcium and vitamin D: No pharmacokinetic interaction has been observed between raloxifene and calcium or vitamin D supplements. Adequate intake of calcium and vitamin D is recommended.
• Laboratory tests: Raloxifene may cause small decreases in serum total alkaline phosphatase, calcium, and phosphate levels, consistent with its bone‑sparing effects. These changes are not clinically significant.

Practical Advice

• Administration: Take one 60 mg tablet once daily at approximately the same time each day, with or without food. Swallow the tablet whole with a glass of water. Adherence to daily dosing is essential for optimal protection against bone loss and breast cancer.
• Monitoring: Bone mineral density (BMD) should be measured at baseline and every 1 to 2 years during treatment. Adequate calcium and vitamin D status should be assessed and supplemented as needed. Patients should be counselled on the signs and symptoms of venous thromboembolism (swelling, pain, or warmth in a leg; sudden chest pain or shortness of breath) and instructed to report these immediately. Any unexplained uterine bleeding should be investigated. In women with pre‑existing hypertriglyceridemia, serum triglycerides should be monitored periodically.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed. Keep out of the reach and sight of children.
• Lifestyle: Raloxifene is most effective as part of a comprehensive osteoporosis management program that includes regular weight‑bearing exercise (walking, jogging, resistance training), smoking cessation, limiting alcohol, and ensuring adequate dietary intake of calcium and vitamin D. Avoid prolonged immobilisation; when travelling, move legs periodically to reduce the risk of blood clots. If you are scheduled for surgery or anticipate prolonged bed rest, inform your doctor so that raloxifene can be temporarily discontinued.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and return to your regular schedule. Do not take a double dose.
• When to seek medical review: Contact your doctor immediately if you experience symptoms of a blood clot: sudden swelling, pain, or warmth in a leg; sharp chest pain that may worsen with deep breathing; coughing up blood; sudden shortness of breath; or sudden severe headache, confusion, or weakness on one side of the body. Report any unexplained uterine bleeding, a new breast lump, or skin changes. Seek emergency care for any of these symptoms.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Bisphosphonates (oral): Alendronate (Fosamax®), risedronate (Actonel®), and etidronate (Didrocal®) are first‑line oral agents for the prevention and treatment of osteoporosis. They work by inhibiting bone resorption and have been shown to reduce the risk of vertebral, non‑vertebral, and hip fractures. They do not have the breast cancer risk‑reducing effects of raloxifene.
• Bisphosphonates (intravenous): Zoledronic acid (Aclasta®) and denosumab (Prolia®) are injectable therapies for osteoporosis that offer more potent fracture protection, including hip fractures. Denosumab is a RANKL inhibitor given subcutaneously every 6 months. These agents do not reduce breast cancer risk.
• Estrogen therapy (hormone replacement therapy, HRT): Combined estrogen‑progestin or estrogen‑alone therapy effectively prevents and treats osteoporosis and reduces vertebral and hip fractures. However, HRT is associated with increased risks of breast cancer, endometrial cancer (with unopposed estrogen), venous thromboembolism, and stroke, and is generally reserved for younger postmenopausal women with significant menopausal symptoms.
• Tamoxifen (Nolvadex®): Another SERM used for breast cancer treatment and prevention. Tamoxifen is more effective than raloxifene at reducing invasive breast cancer risk but is associated with a higher risk of endometrial cancer and more severe hot flushes. It is approved for breast cancer prevention in high‑risk pre‑ and postmenopausal women in Canada, whereas raloxifene is only approved for postmenopausal women.
• Other SERMs in development: Bazedoxifene is used in combination with conjugated estrogens for menopausal symptoms and osteoporosis prevention; it is not available as a single agent in Canada for osteoporosis.
• Non‑pharmacological approaches: A diet rich in calcium and vitamin D, regular weight‑bearing exercise, smoking cessation, moderation of alcohol, and fall‑prevention strategies are essential components of any osteoporosis management plan and can be used alone in mild cases or in combination with pharmacotherapy.

Clinical Efficacy

The efficacy of raloxifene has been demonstrated in large, randomised, double‑blind, placebo‑controlled clinical trials. The MORE (Multiple Outcomes of Raloxifene Evaluation) trial, involving over 7,700 postmenopausal women with osteoporosis, demonstrated that raloxifene 60 mg daily reduced the risk of new vertebral fractures by 30‑50% compared with placebo over 3 years, with the benefit evident as early as the first year. Raloxifene also significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck by approximately 2‑3% over 3 years. However, raloxifene did not significantly reduce the risk of non‑vertebral or hip fractures in the MORE study. The CORE (Continuing Outcomes Relevant to Evista) trial extended follow‑up to 8 years and confirmed the sustained vertebral fracture benefit. The STAR (Study of Tamoxifen and Raloxifene) trial, which included over 19,000 postmenopausal women at increased risk of breast cancer, demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer, with a 50% reduction compared with placebo, but with a significantly lower risk of endometrial cancer and thromboembolic events. Based on these data, raloxifene is approved by Health Canada for the prevention and treatment of postmenopausal osteoporosis and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk of breast cancer. Osteoporosis Canada guidelines list raloxifene as an option for postmenopausal women with osteoporosis who are at increased risk of breast cancer and for whom bisphosphonates are not suitable. The Canadian National Breast Screening Study and the Canadian Task Force on Preventive Health Care recognize raloxifene as a preventive option for breast cancer in postmenopausal women at high risk, alongside tamoxifen.

Important:

Raloxifene is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It can increase the risk of life‑threatening venous thromboembolism (blood clots in the legs or lungs). Do not take raloxifene if you have a history of blood clots, are immobilized for prolonged periods, or are pregnant or may become pregnant. Discontinue raloxifene and seek immediate medical attention if you develop symptoms of a blood clot, such as sudden leg pain, swelling, or redness; sharp chest pain; shortness of breath; or coughing up blood. Raloxifene is also associated with a small increase in the risk of fatal stroke. Do not use raloxifene together with systemic estrogen or hormone replacement therapy. Adequate calcium and vitamin D intake is necessary; supplementation may be required. If you are scheduled for surgery or anticipate prolonged bed rest, inform your doctor so that raloxifene can be temporarily discontinued. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Raloxifene - Shipping across Canada